1. COVID-19 infection: the perspectives on immune responses. (2020) Cell Death & Differentiation volume 27, pages1451–1454. https://doi.org/10.1016/j.jbspin.2020.03.011

2. Covid-19 Does Not Lead to a “Typical” Acute Respiratory Distress Syndrome. (2020) AJRCCM, in press. https://doi.org/10.1164/rccm.202003-0817LE

3. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. (2020) Preprint at bioRxiv. https://doi.org/10.1101/2020.03.14.988345

4. Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue. (2020) Preprint at bioRxiv. https://doi.org/10.1101/2020.04.07.030742

5. Accelerated hyaluronan concentration as the primary driver of morbidity and mortality in high-risk COVID-19 patients: with therapeutic introduction of an oral hyaluronan inhibitor in the prevention of “Induced Hyaluronan Storm” Syndrome. (2020) Preprint at medRxiv. https://doi.org/10.1101/2020.04.19.20071647

5. Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the surface protein (spike) S1 receptor binding domain with heparin. (2020) Preprint at bioRxiv. https://doi.org/10.1101/2020.04.28.066761

6. Glycosaminoglycan binding motif at S1/S2 proteolytic cleavage site on spike glycoprotein may facilitate novel coronavirus (SARS-CoV-2) host cell entry. (2020) Preprint at bioRxiv. https://doi.org/10.1101/2020.04.14.041459

7. The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding. (2020) Preprint at bioRxiv. https://doi.org/10.1101/2020.02.29.971093

8. Central nervous system manifestations of COVID-19: A systematic review. (2020) Journal of the Neurological Sciences 413, 16832. https://doi.org/10.1016/j.jns.2020.116832

9. Clinical classifiers of COVID-19 infection from novel ultra-high-throughput proteomics. (2020) Preprint at medRxiv. https://doi.org/10.1101/2020.04.27.20081810

10. Correlation analysis of the severity and clinical prognosis of 32 cases of patients with COVID-19. (2020) Respiratory Medicine, in press. https://doi.org/10.1016/j.rmed.2020.105981

11. COVID-19: Transmission, prevention, and potential therapeutic opportunities. (2020) Clin Chim Acta. Sep; 508: 254-266. https://doi.org/10.1016/j.cca.2020.05.044

12. Molecular Alterations Prompted by SARS-CoV-2 Infection: Induction of Hyaluronan, Glycosaminoglycan and Mucopolysaccharide Metabolism. (2020) Arch Med Res. Jun; S0188-4409(20)30705-0. https://doi.org/10.1016/j.arcmed.2020.06.011

13. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. (2020) Cell https://doi.org/10.1016/j.cell.2020.09.033

14. Hyaluronan is abundant in COVID-19 respiratory secretions. (2020) Preprint at medRxiv. https://medrxiv.org/cgi/content/short/2020.09.11.20191692v1

15. Presence of hyaluronan in lung alveoli in severe Covid-19 – an opening for new treatment options? (2020) JBC https://doi.org/10.1074/jbc.AC120.015967

16. IL-13 is a driver of COVID-19 severity. (2021) Preprint at medRxiv. https://doi.org/10.1101/2020.06.18.20134353

17. Hymecromone: A Clinical Prescription Hyaluronan Inhibitor for Efficiently Blocking COVID-19 Progression. (2021) Preprint at medRxiv  https://doi.org/10.1101/2021.10.19.21263786